2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2890

Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Abstract Number: 926

Does a Family History of Total Knee Replacement for Knee Osteoarthritis Influence Knee Pain and Structural Progression? a Prospective Longitudinal Cohort Study
Abstract Number: 503

Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Abstract Number: 2273

Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? : A Preliminary Assessment of a Single Center Experience
Abstract Number: 239

Does Adjusting BMI for Lean Mass Deficits Affect Calculated Fracture Risk Using FRAX in Rheumatoid Arthritis?
Abstract Number: 1657

Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Abstract Number: 1309

Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Abstract Number: 1092

Does Arthritis Status Predict Starting or Stopping Work over a 2-Year Period?
Abstract Number: 2492

Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
Abstract Number: 2913

Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Abstract Number: 2225

Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies?
Abstract Number: 1993

Does Psychological Safety Impact Learning Environments Among Rheumatology Fellows: Findings from Veterans Affairs Learners’ Perception Survey
Abstract Number: 3014

Does the Order or Amount of Risk-Benefit Information Presented Influence patients’ Perceived Value of a Proposed New Medication?
Abstract Number: 1480

Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
Abstract Number: 515

Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].